Journal of International Oncology››2016,Vol. 43››Issue (3): 204-206.doi:10.3760/cma.j.issn.1673422X.2016.03.011

Previous ArticlesNext Articles

Advance of radioiodine antagonist related gene of differentiated thyroid carcinoma

Yu Yunfang, Ge Minghua

  1. Medical Department of Soochow University, Suzhou 215000, China
  • Online:2016-03-08Published:2016-02-03
  • Contact:Ge Minghua, Email: gemingh@163.com E-mail: gemingh@163.com
  • Supported by:

    Medical and Health Platform Program of Zhejiang Province of China (2015DTA003); Subproject of National High Technology Research and Development Program of China (863 Program) (03-GZ-YX-001)

Abstract:Thyroid carcinomas are the most common endocrine malignancies, and the overwhelming majority of them is differentiated thyroid carcinoma (DTC). The major therapies of DTCs are surgical resection, thyroid stimulating hormone (TSH) inhibitory treatment and iodine radioisotope (131I) treatment. 131I has been widely applied for the diagnosis and treatment of DTC, however, part of these patients may reduce or loss the uptake capacity of131I owing to the alteration of sodium-iodide symporter gene, BRAF, paired box 8, microRNA and cytokeratin 19. These genes are particularly important in the treatment of DTC, which can be used as biomarkers in the treatment efficacy evaluation.

Key words:Thyroid neoplasms,Iodine radioisotopes,Genes